NORWOOD, MA–(Marketwired – Aug 19, 2015) – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and […]
Featured Posts
Closely held Intarcia Therapeutics Inc. said its implantable drug-delivery pump proved superior to Merck MRK -0.42 % & Co.’s top-selling drug Januvia in helping diabetes patients control blood sugar in […]
BONITA, CA–(Marketwired – August 17, 2015) – PharmaCyte Biotech Inc. (OTCQB: PMCB) has made a name for itself with the company’s potentially game-changing pancreatic cancer treatment, and also as the […]
YONKERS, NY–(Marketwired – Aug 17, 2015) – ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody […]
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that in the large pivotal Phase II study, BIRCH, the investigational cancer […]
The Food and Drug Administration pushed back the decision date on an expanded use of Bristol-Myers Squibb Co.’s cancer drug Opdivo to Nov. 27, Bristol-Myers said Wednesday. Bristol-Myers, which initially […]
Juno Therapeutics Inc.’s second-quarter loss widened as the biopharmaceutical company logged higher expenses as it ramps up operations following its December initial public offering. Research-and-development expenses surged to $60.2 […]
Immunotherapy is being hailed as the future of cancer treatment. Harnessing the body’s own immune system to attack and kill cancer cells, immunotherapy is a burgeoning field of medicine that […]
An experimental vaccine offers total protection against Ebola, according to preliminary results from a large clinical trial. Among 4,000 vaccinated people, there were no cases of infection. The study concluded […]
LOUISVILLE, CO–(Marketwired – August 04, 2015) – GlobeImmune, Inc. (NASDAQ: GBIM) announced today that Celgene Corporation exercised its option under the 2009 Collaboration and Option Agreement to exclusively license GI-6207, […]